Welcome back to another edition of Endpoints Weekly. Thanks to everyone who came out to our AI Day event this week in New ...
🇬🇧 Catalent to sell UK site to Codis: The CDMO is set to take Catalent’s oral solid dose factory in Nottingham, with the transaction expected to close in the third quarter of this year.
Eli Lilly's neuroscience president Carole Ho expressed interest in ibogaine R&D at NYC's Psychedelic Healthcare Forum, ...
Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a ...
China's Commerce Ministry proposes restricting export of cell/gene therapy, siRNA, and pathogen tech, while preserving drug ...
Research shows 952K+ US clinicians made 271M queries to AI tool OpenEvidence from Jan 2024–June 2026. But there are concerns ...
More former Genentech leaders are finding a new home. Lélia Delamarre posted on LinkedIn that she’s leading R&D at ARCH-backed cancer biotech Medici Therapeutics, one of this year’s Endpoints 11 ...
NorthStar/Quarkmed, Lonza/Qurient CDK7 deal, Triastek/J&J 3D printing pact, Scinai's $5.1M deal & HydRegen's $8M Series A led ...
Paul Stoffels’ new Armed Cell Therapeutics buys Lakefront’s (ex-Galapagos) preclinical CAR-T work for $9M upfront, $230M in ...
Ultragenyx sold 2 PRVs for $203M and $210M; Biomea's BMF-650 showed modest weight loss; Skyhook Bio shutters; Altay raises ...
OMass has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the ...
New-to-me terms: Agents (for booking healthcare appointments and accessing patient portals) and abundance (the idea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results